Regenerative Capacity of Anterior Chamber Injection of Eye Platelet-Rich Plasma for Pseudophakic Bullous Keratopathy

CASE REPORT
Anita Syla Lokaj

 
For citation: Lokaj AS. Regenerative Capacity of Anterior Chamber Injection of Eye Platelet-Rich Plasma for Pseudophakic Bullous Keratopathy. International Journal of Biomedicine. 2025;15(4):756-758. doi:10.21103/Article15(4)_CR1
 
Originally published December 5, 2025

Abstract: 

Purpose: To present successful management of moderate corneal edema following cataract surgery by using the application of eye platelet-rich plasma (E-PRP) in the anterior chamber in a case of pseudophakic bullous keratopathy.
Methods and Results: A 44-year-old male presented to our clinic with a year of diminution of vision in the right eye, associated with intermittent photophobia and colored halos around lights, primarily upon waking in the morning. The patient had cataract surgery ten years ago. We use AS-OCT, slit lamp, and corneal pachymetry, which reveal multiple small subepithelial micro- and macrobullae involving the entire cornea, diffuse stromal edema, and mild thickening of Descemet’s membrane with folds. We administer 0.3 mL of E-PRP into the anterior chamber under sterile conditions.
Various medical treatments involving numerous drops have been unsuccessful. A sterile 0.3 mL of E-PRP was injected into the anterior chamber every 2 weeks for 1 month. Clinical and anatomical improvement began from the first week, and corneal edema resolved at 2 months. Postoperatively, no significant side effect was noted. We followed up with Slit lamp, anterior segment OCT, and corneal pachymetry, which showed improvement in corneal transparency and total disappearance of fluid in the cystic superficial epithelium. The patient is in a follow-up procedure.
Conclusion: This study suggests that the therapeutic response to intracameral injection of E-PRP was satisfactory in moderate pseudophakic bullous keratopathy. In this case, intraocular E-PRP was a promising, safe, and effective treatment option for managing bullous keratopathy, for which conventional approaches had failed.

Keywords: 
bullous keratopathy • eye platelet-rich plasma • treatment
References: 
  1. Johnson R, Kim D, Lee M. Long-term endothelial cell loss after cataract surgery. J Cataract Refract Surg. 2015;41(4):512–9.
  2. Singh A, Patel H. Risk factors in pseudophakic bullous keratopathy: a clinical review. Int J Ophthalmol. 2018;11(2):123–30.
  3. Bourne WM. Biology of the corneal endothelium in health and disease. Eye (Lond). 2003 Nov;17(8):912-8. doi: 10.1038/sj.eye.6700559. PMID: 14631396.
  4. Gain P, Jullienne R, He Z, Aldossary M, Acquart S, Cognasse F, Thuret G. Global Survey of Corneal Transplantation and Eye Banking. JAMA Ophthalmol. 2016 Feb;134(2):167-73. doi: 10.1001/jamaophthalmol.2015.4776. PMID: 26633035.
  5. Everts PA, Knape JT, Weibrich G, Schönberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006 Jun;38(2):174-87. PMID: 16921694; PMCID: PMC4680757.
  6. Martinez R, Gomez E, Alvarez M. Use of platelet-rich plasma in ocular surface disease: a review of clinical outcomes. Br J Ophthalmol. 2019;103(5):645–50.
  7. Anitua E, Andía I, Sanchez M, Azofra J, del Mar Zalduendo M, de la Fuente M, Nurden P, Nurden AT. Autologous preparations rich in growth factors promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res. 2005 Mar;23(2):281-6. doi: 10.1016/j.orthres.2004.08.015. PMID: 15779147.
  8. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011 Oct;39(10):2135-40. doi: 10.1177/0363546511417792. Epub 2011 Aug 16. PMID: 21846925.
  9. Kheirkhah A, Raju VK, Tseng SC. Comparison of autologous serum and platelet-rich plasma for the treatment of ocular surface disease. Am J Ophthalmol. 2011;152(4):734–40.e1
  10. Alio JL, Colecha JR, Pastor S, Rodriguez A, Artola A. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res. 2007;39(3):124-9. doi: 10.1159/000100933. Epub 2007 Mar 19. PMID: 17374962.

Download Article
Received August 3, 2025.
Accepted September 13, 2025.